Almac Group Invests £1 Million in Dedicated Mass Spectrometry Laboratory
Published: Oct 21, 2011
The £1M facility houses state-of-the-art mass spectrometers and underlines Almac’s commitment to providing the best analytical facilities for its customers. The investment of this laboratory and instruments substantially increases the company’s capabilities in solving complex analytical challenges. Instrumentation includes Quadrupole Time of Flight and Triple Quadrupole spectrometers for accurate mass and quantitation work.
With this dedicated facility, clients can now benefit from an extended range of mass spectrometry services, including the quantitation of genotoxic impurities, bioanalysis, structure elucidation, isotopic purity determinations and high resolution mass spectrometry of both small and large molecules.
Jon Cook, Head of Analytical Chemistry commented “This new mass spectrometry facility reinforces Almac’s vision of delivering the best for our customers and substantially enhances the level and depth of services we can provide.”
Paul Desmond, Analytical Manager added “We are delighted with this investment – whilst customer focus is always our priority, we are confident that the enhanced services offered within our facility, will benefit our clients further.”
Agilent Technologies were chosen as the preferred vendor to supply the suite of Mass Spectrometers to Almac. Agilent Technologies are a company of innovation, that deliver high quality products and technical solutions which will help enable Almac meet their clients expanding analytical requirements.
Declan Murray, Sales Manager noted “Agilent Technologies are delighted to be part of setting up such an important new Mass Spectrometry Laboratory in Almac. Agilent have a long relationship with Almac and the new MS facility merely builds and strengthens this relationship further.”
For further information, Almac will be exhibiting at the forthcoming CPhI (Booth 41C18) and AAPS (Booth 2837) conferences.
For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 861 3938 or e-mail: firstname.lastname@example.org.
The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Almac has now moved into its new North American Headquarters located in Souderton PA.